Drug Type Small molecule drug |
Synonyms AC480, BMS 599626, BMS-599626 + [1] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H28ClFN8O3 |
InChIKeyCOUSSRGSHIJMMN-FTBISJDPSA-N |
CAS Registry873837-23-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malignant glioma of brain | Phase 1 | US | 01 Nov 2009 | |
Recurrent Glioma | Phase 1 | US | 01 Nov 2009 | |
HER2-Expressing Cancers | Phase 1 | FR | 01 May 2004 | |
HER2-Expressing Cancers | Phase 1 | ES | 01 May 2004 | |
Refractory Malignant Solid Neoplasm | Phase 1 | FR | 01 May 2004 | |
Refractory Malignant Solid Neoplasm | Phase 1 | ES | 01 May 2004 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 01 Mar 2004 | |
Neoplasm Metastasis | Phase 1 | US | 01 Mar 2004 |
Phase 1 | - | ppvpmoccla(zomwrcokfz) = wrirqhryev deflkevaqs (vnkzrnjqqx ) View more | - | 01 Jun 2005 | |||
Phase 1 | 13 | ruxgvpyhgr(ixqivjadop) = cgisqglrxy pyovvwtglg (sweqlxfgpk ) View more | - | 01 Jun 2005 |